About Akita Biosciences

Akita Biosciences develops intranasal therapies that enhance the body's innate immune response to airborne pathogens, such as those causing respiratory infections. By utilizing rapid absorption technology, these nasal sprays provide a non-invasive method for delivering therapeutic agents directly into the bloodstream, improving defense against infections like the cold, flu, and COVID-19.

```xml <problem> Respiratory infections, such as the cold, flu, and COVID-19, are often initiated in the nasal passages by airborne pathogens. While the nasal passages have natural defenses, these are often insufficient to prevent infection. </problem> <solution> Akita Biosciences develops intranasal therapies designed to enhance the body's innate immune response to airborne pathogens. Their nasal sprays utilize rapid absorption technology to deliver therapeutic agents directly into the bloodstream via the nasal passages, bolstering defenses against respiratory infections. By amplifying the body's natural defense system, Akita Biosciences aims to trigger a more robust and effective immune response, generating a broad-spectrum defense against a wide range of respiratory infections. This non-invasive method offers rapid therapeutic benefits, typically occurring within minutes. </solution> <features> - Nasal spray formulation for direct delivery of therapeutic agents to the nasal passages. - Rapid absorption technology enabling quick entry into the bloodstream. - Enhancement of the body's innate immune response. - Broad-spectrum immune response against various respiratory infections. - Non-invasive administration. </features> <target_audience> The primary target audience includes individuals seeking to proactively defend against airborne respiratory infections, as well as those looking for a non-invasive method of immune support. </target_audience> ```

What does Akita Biosciences do?

When was Akita Biosciences founded?

Akita Biosciences was founded in 2022.

Founded

2022

Employees

7 employees

Major Investors

Flu Lab

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Akita Biosciences

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

akitabiosciences.com 700+

Crunchbase

Founded 2022

Funding

Major Investors

Flu Lab

Team (5+)

No team information available.

Company Description

Problem

Respiratory infections, such as the cold, flu, and COVID-19, are often initiated in the nasal passages by airborne pathogens. While the nasal passages have natural defenses, these are often insufficient to prevent infection.

Solution

Akita Biosciences develops intranasal therapies designed to enhance the body's innate immune response to airborne pathogens. Their nasal sprays utilize rapid absorption technology to deliver therapeutic agents directly into the bloodstream via the nasal passages, bolstering defenses against respiratory infections. By amplifying the body's natural defense system, Akita Biosciences aims to trigger a more robust and effective immune response, generating a broad-spectrum defense against a wide range of respiratory infections. This non-invasive method offers rapid therapeutic benefits, typically occurring within minutes.

Features

Nasal spray formulation for direct delivery of therapeutic agents to the nasal passages.

Rapid absorption technology enabling quick entry into the bloodstream.

Enhancement of the body's innate immune response.

Broad-spectrum immune response against various respiratory infections.

Non-invasive administration.

Target Audience

The primary target audience includes individuals seeking to proactively defend against airborne respiratory infections, as well as those looking for a non-invasive method of immune support.